{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:06:36Z","timestamp":1779102396026,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd008386.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T00:00:00Z","timestamp":1323216000000}}],"reference-count":49,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008386.pub3","type":"journal-article","created":{"date-parts":[[2011,12,5]],"date-time":"2011-12-05T21:40:32Z","timestamp":1323121232000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Statins for multiple sclerosis"],"prefix":"10.1002","author":[{"given":"Jin","family":"Wang","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital, Guangxi Medical University; Department of Neurology; No. 22, Shuang Yong Lu Nanning Guangxi China 530021"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousheng","family":"Xiao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Guangxi Medical University; Department of Neurology; No. 22, Shuang Yong Lu Nanning Guangxi China 530021"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Luo","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Guangxi Medical University; Department of Neurology; No. 22, Shuang Yong Lu Nanning Guangxi China 530021"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongye","family":"Luo","sequence":"additional","affiliation":[{"name":"Guangxi Medical University; Dept. of Epidemiology & Statistics; No. 22, Shuang Yong Lu Nanning Guangxi China 530021"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,7]]},"reference":[{"issue":"18","key":"10.1002\/14651858.CD008386.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000319698.40024.1c","article-title":"Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis","volume":"71","author":"Birnbaum","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD008386.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/1352458509358909","article-title":"Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy","volume":"16","author":"Lanzillo","year":"2010","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0003|cit3","first-page":"S56","article-title":"An open label randomised clinical trial of atorvastatin in combination with IFN beta-1a in active MS patients: 12 months results","volume":"13","author":"Orefice","year":"2007","journal-title":"Multiple Sclerosis"},{"issue":"8","key":"10.1002\/14651858.CD008386.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S1474-4422(11)70144-2","article-title":"Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial","volume":"10","author":"Sorensen","year":"2011","journal-title":"Lancet neurology"},{"issue":"7","key":"10.1002\/14651858.CD008386.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458510369147","article-title":"Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double blind randomized controlled trial","volume":"16","author":"Togha","year":"2010","journal-title":"Multiple Sclerosis"},{"issue":"10","key":"10.1002\/14651858.CD008386.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/archneur.64.10.nct70002","article-title":"Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1\/2 trial","volume":"64","author":"Bar-Or","year":"2007","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0007|cit7","unstructured":"Laplaud DA Lefrere F Auffray-Calvier E Nguyen J Edan G Page EL Safety, tolerance and efficacy of Pravastatin in MS-STEP in multiple sclerosis: a randomized double-blind placebo controlled pilot study ECTRIMS, 24th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; 2008 Sept 17-20; Montreal, Canada 2008"},{"issue":"4","key":"10.1002\/14651858.CD008386.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"e1928","DOI":"10.1371\/journal.pone.0001928","article-title":"Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis","volume":"3","author":"Paul","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0009|cit9","first-page":"S57","article-title":"Effects of statins on intramuscular interferon beta-1afor relapsing-remitting multiple sclerosis","volume":"13","author":"Rudick","year":"2007","journal-title":"Multiple Sclerosis"},{"issue":"23","key":"10.1002\/14651858.CD008386.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1212\/WNL.0b013e3181a92b96","article-title":"Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a","volume":"72","author":"Rudick","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008386.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00415-003-1070-8","article-title":"Therapeutic potential of lovastatin in multiple sclerosis","volume":"250","author":"Sena","year":"2003","journal-title":"Journal of Neurology"},{"issue":"9421","key":"10.1002\/14651858.CD008386.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(04)16205-3","article-title":"Oral simvastatin treatment in relapsing-remitting multiple sclerosis","volume":"363","author":"Vollmer","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD008386.pub3-BIB0013|cit13","first-page":"694","article-title":"The efficacy of Simvastatin and Corticosteroid Combination Therapy in Multiple Sclerosis","volume":"10","author":"Wang","year":"2008","journal-title":"Journal of Chinese Physician"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0014|cit14","unstructured":"NCT00942591 Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b (SWABIMS) clinicaltrials.gov\/ct2\/show\/NCT00942591"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0015|cit15","unstructured":"NCT01111656 SWABIMS Follow Up-study clinicaltrials.gov\/ct2\/show\/NCT01111656"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0016|cit16","unstructured":"\u00d6ztekin NS \u00d6ztekin FM Munis OB Atorvastatin combined with interferon beta 1a in relapsing-remitting multiple sclerosis: preliminary results of a 24 month randomized open-label clinical trial ECTRIMS, 24th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0017|cit17","unstructured":"NCT00242268 A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis clinicaltrials.gov\/ct2\/show\/NCT00242268"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0018|cit18","unstructured":"NCT00429442 Simvastatin as an Add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis clinicaltrials.gov\/ct2\/show\/NCT00429442"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0019|cit19","unstructured":"NCT00647348 Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis (MS-STAT) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00647348"},{"issue":"6","key":"10.1002\/14651858.CD008386.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.20021425","article-title":"Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin","volume":"197","author":"Aktas","year":"2003","journal-title":"The Journal of Experimental Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008386.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1474-4422(03)00256-4","article-title":"Potential of statins for the treatment of multiple sclerosis","volume":"2","author":"Baker","year":"2003","journal-title":"Lancet Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008386.pub3-BIB0022|cit22","first-page":"543","article-title":"Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials","volume":"57","author":"Boutron","year":"2004","journal-title":"Epidemiology"},{"issue":"9313","key":"10.1002\/14651858.CD008386.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0024|cit24","unstructured":"D'Amico R Ebers G Filippini G Fredrikson S Di Pietrantonj C Khan F Cochrane Multiple Sclerosis Group About The Cochrane Collaboration 2009"},{"issue":"8","key":"10.1002\/14651858.CD008386.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"e3081","DOI":"10.1371\/journal.pone.0003081","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias","volume":"3","author":"Dwan","year":"2008","journal-title":"PloS one"},{"issue":"2","key":"10.1002\/14651858.CD008386.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1517\/14656560802677882","article-title":"High-dose, high-frequency recombinant interferon beta-1ain the treatment of multiple sclerosis","volume":"10","author":"Hartung","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0027|cit27","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD008386.pub3-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000006.pub3","article-title":"Publication bias in clinical trials due to statistical significance or direction of trial results","author":"Hopewell","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9326","key":"10.1002\/14651858.CD008386.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD008386.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0031|cit31","unstructured":"Lefebrvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT,Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD008386.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008386.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.4049\/jimmunol.172.2.1273","article-title":"Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy","volume":"172","author":"Nath","year":"2004","journal-title":"Journal of Immunology"},{"issue":"2","key":"10.1002\/14651858.CD008386.pub3-BIB0034|cit34","first-page":"S56","article-title":"An open label randomised clinical trial of atorvastatin in combination with IFN beta-1a in active MS patients: 12 months results","volume":"13","author":"Orefice","year":"2007","journal-title":"Multiple Sclerosis"},{"issue":"11","key":"10.1002\/14651858.CD008386.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1096\/fj.05-3861com","article-title":"HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis","volume":"19","author":"Paintlia","year":"2005","journal-title":"The FASEB journal"},{"issue":"1-2","key":"10.1002\/14651858.CD008386.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jneuroim.2006.06.005","article-title":"Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis","volume":"178","author":"Peng","year":"2006","journal-title":"Journal of Neuroimmunology"},{"issue":"6","key":"10.1002\/14651858.CD008386.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic Criteria for Multiple Sclerosis: 2005 revisions to the Macdonald Criteria","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD008386.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of neurology"},{"issue":"3","key":"10.1002\/14651858.CD008386.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0040|cit40","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"5","key":"10.1002\/14651858.CD008386.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Shulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008386.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"c7153","DOI":"10.1136\/bmj.c7153","article-title":"Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists","volume":"342","author":"Smyth","year":"2011","journal-title":"BMJ (Clinical research ed.)"},{"issue":"2","key":"10.1002\/14651858.CD008386.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3940(99)00414-0","article-title":"Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin","volume":"269","author":"Stanislaus","year":"1999","journal-title":"Neuroscience Letters"},{"issue":"2","key":"10.1002\/14651858.CD008386.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jnr.1207","article-title":"Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis","volume":"66","author":"Stanislaus","year":"2001","journal-title":"Journal of Neuroscience Research"},{"issue":"3","key":"10.1002\/14651858.CD008386.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0304-3940(02)00943-6","article-title":"Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin","volume":"333","author":"Stanislaus","year":"2002","journal-title":"Neuroscience Letters"},{"issue":"2","key":"10.1002\/14651858.CD008386.pub3-BIB0046|cit46","first-page":"S25","article-title":"Does simvastatin antagonise the effect of interferon beta? Interim safety analysis of the ongoing SIMCOMBIN study","volume":"13","author":"S\u00f8rensen","year":"2007","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD008386.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Quality of Life Research"},{"issue":"1469-493X (Elec","key":"10.1002\/14651858.CD008386.pub3-BIB0048|cit48","first-page":"CD008386","article-title":"Statins for multiple sclerosis","volume":"12","author":"Wang","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"6911","key":"10.1002\/14651858.CD008386.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","article-title":"The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease","volume":"420","author":"Youssef","year":"2002","journal-title":"Nature"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008386.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:19:49Z","timestamp":1628547589000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008386.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,12,7]]},"references-count":49,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008386.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,7]]}}}